Damian Crowther joined SV as a Venture Partner in the Dementia Discovery Fund in 2022.
Damian undertook medical training at Cambridge and Oxford, specialising in neurology. He combined clinical work with academic leadership of a dementia-focused research group at the University of Cambridge. With increasing focus on therapeutic application, he joined AstraZeneca Neuroscience in Cambridge and worked for six years developing small molecule, biologic and new modality therapies for dementias. Having caught the entrepreneurial bug at AstraZeneca he has worked as Entrepreneur in Residence at all three vertices of the UK’s golden triangle: Oxford Science Enterprises, Cambridge Innovation Capital and in the London office of the Dementia Discovery Fund.
Damian’s scientific passion is to understand and then exploit for therapeutic benefit, the science of (nucleo)protein aggregation as it pertains to inflammation and neurodegeneration. Whether it be working for big biopharma or helping to launch ambitious new start-ups, the goals are always the same: benefits for patients and returns for founders and investors.
In his spare time Damian creates medical websites, tends the garden and runs half marathons slowly.
Academic credentials:
Undergraduate degree and PhD, University of Cambridge; BM BCh, University of Oxford; Fellow of the Royal College of Physicians, London.
